Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02417116
Other study ID # TP00128
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2015
Est. completion date January 2019

Study information

Verified date January 2019
Source Aston University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Millions of people suffer from dry eye disease, causing symptoms such as redness, burning, feeling of sand or grit in the eye and light sensitivity. Dry eye disease occurs when your eyes do not produce enough tears or produce poor quality tears. This can happen for a number of reasons, including aging, hormonal changes in women and side effects of diseases or medications.

It is now possible to objectively measure the degree of dry eye disease by collecting a tiny sample of tears from the corner of the eye and then measuring the amount of salt in the tears (termed osmolarity). We aim to establish the overall levels of raised and normal tear osmolarity in people presenting to the eye clinic with complaints of dry eye, and relate this to other factors such as symptoms, topical and nutritional medication and dry eye treatment.


Description:

This study will investigate the efficacy of two treatment non-pharmaceutical therapies (tear drop alone, tear drop combined with omega 3 nutritional supplement and warm compresses) for dry eye reporting patients against a control (saline) over a 3 month period. A relatively new clinical measure (osmolarity) will be performed alongside traditional tear film volume, tear film stability, gland integrity and ocular surface damage measures to determine how this influences symptomatic complaints.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Dry Eye Symptoms SPEED >8

Exclusion Criteria:

- Unable to participate in 90 days therapy

- Allergic to therapy

- On medication known to affect ocular surface / tear film

- Had ocular trauma, infection or surgery

- Diagnosed with a medical condition known to affect ocular surface / tear film

Study Design


Intervention

Other:
Tear supplement
Application as required to improve comfort
Tear supplement 2
Application as required to improve comfort
Dietary Supplement:
Omega 3 nutrition supplement
Taken each day
Device:
Eye bag
Applied following microwave heating to closed eyelids for 5 minutes each day
Other:
Saline
Application as required to improve comfort

Locations

Country Name City State
United Kingdom Black & Lizars Optometrists Ayr
United Kingdom Robert Frith Opticians Blandford Forum Dorset
United Kingdom Robert Frith Opticians Gillingham Dorset
United Kingdom Black & Lizars Optometrists Glasgow
United Kingdom Robert Frith Opticians Shaftesbury Dorest
United Kingdom Robert Frith Opticians Twickenham Middlesex

Sponsors (2)

Lead Sponsor Collaborator
Aston University TearLab Corporation

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Osmolarity change Salt balance in tears measured with the Tearlab 3 months
Secondary Tear break-up time change Tear stability following a blink 3 months
Secondary Corneal staining change Fluorescein dye applied to the ocular surface and observed with blue light and a yellow filter to observe staining fluorescence 3 months
Secondary Meibomian gland change Grading of meibomian glands using Oxford scale 3 months
Secondary Tear Meniscus Height Height of tear meniscus along the lower lid margin observed through a slit-lamp microscope 3 months
Secondary SPEED Questionnaire change Dry eye symptomology questionnaire 3 months
See also
  Status Clinical Trial Phase
Completed NCT05102409 - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease Phase 2
Completed NCT05027087 - The Effect of a Novel Blueberry Supplement on Dry Eye Disease Phase 3
Completed NCT06159569 - Performance and Tolerability of the Medical Device LACRIACT N/A
Completed NCT04081610 - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Phase 1
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT03418727 - Dry Eye Disease Study With Brimonidine Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Recruiting NCT04527887 - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) Phase 4
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT05618730 - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B Phase 1
Completed NCT04553432 - Dry Eye OmniLenz Application of Omnigen Research Study Phase 4
Recruiting NCT04109170 - Dry Eye Evaluation System Based on Bioinformatics
Completed NCT04105842 - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type N/A
Completed NCT05505292 - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers Phase 4
Completed NCT04668131 - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease N/A
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02235259 - Efficacy and Safety of XG-104 for the Treatment of Dry Eye Phase 2
Not yet recruiting NCT02218827 - Topical Steroid Treatment For Dry Eye N/A
Completed NCT01959854 - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye N/A